drugset / Trial / NCT02825719

Ulipristal Use in Chinese Population

NCT02825719

Phase 4 Terminated 31 enrolled Queen Mary Hospital, Hong Kong
RandomizedParallel-groupTriple-blindTreatment

Summary

Uterine leiomyomas is the commonest benign tumour of the female genital tract. It lead to menorrhagia, anaemia, pain and pressure symptoms. Due to the enlarged uterus, the use of minimal invasive surgery is limited. There is also increase risk of intraoperative blood transfusion. Ulipristal acetate (UPA) is a selective progesterone-receptor modulator (SPRM). Preoperative use of Ulipristal for 12 weeks has been shown to decrease uterine bleeding, fibroid volume, pre-operative anaemia and symptoms severity. However there is still lacking evidence in terms of long term safety and efficacy, especially in Chinese population. The aim of the present study is to evaluate the effect and safety on preoperative use of Ulipristal on fibroid.

Timeline

Start
2015-12-02
Primary completion
2020-03-31
Completion
2020-03-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ulipristal Acetate Unknown 5 mg Oral
Background Ferrous Sulfate Diagnostic / imaging agent 300 mg
Background Tranexamic Acid Small molecule 500 mg

Indications